






Severe asthma can be uncontrolled despite treatment;¹ suboptimal control can impact outcomes and quality of life²⁻⁷

In ISAR, ~50% of patients with severe asthma in the USA were poorly controlled despite therapy^{1*}



There are many consequences of suboptimal asthma control

-  Serious exacerbations requiring hospitalization or emergency room visits^{2,3}
-  Poor quality of life⁴ (eg, activity limitation)
-  OCS use,² which can lead to serious adverse outcomes⁵
-  High healthcare resource utilization/ greater economic burden^{2,3,6,7}

*The ISAR study included US patients (N=3286) receiving GINA Step 5 treatment and those uncontrolled with GINA Step 4 treatment. Asthma control was defined using the ACT or ACQ questionnaire, and patients were categorized as 'poorly controlled', 'not well controlled', or 'well controlled'. n=876 US patients were included in the analysis presented in the figure¹

ACT, Asthma Control Test; ACQ, Asthma Control Questionnaire; GINA, Global Initiative for Asthma; ISAR, International Severe Asthma Registry; OCS, oral corticosteroid(s)

1. Wang E, et al. *Chest*. 2020;157:790–804. 2. Nagase H, et al. *Allergol Int*. 2020;69:53–60. 3. Sullivan SD, et al. *Allergy*. 2007;62:655–660. 4. Chen H, et al. *J Allergy Clin Immunol*. 2007;120:396–402.

5. Price DB, et al. *J Asthma Allergy*. 2018;11:193–204. 6. Chen S, et al. *Curr Med Res Opin*. 2018;34:2075–2088. 7. Sullivan SD, et al. *Allergy*. 2007;62:126–133.

US-59566 Last Updated 11/21. © 2021 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored by Amgen and AstraZeneca.